AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05430867
Drug: Memantine Oral Tablet
RxNorm normalized name: memantine Oral Tablet
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine 20mg once-daily
Trial: NCT05350189
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At discretion of attending physician
Trial: NCT05331742
Drug: Vaccine
RxNorm normalized name: VACCINES
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients who have received vaccine against coronavirus disease infection
Trial: NCT04928352
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
Trial: NCT04928352
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
Trial: NCT00497120
Drug: acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04785924
Drug: Imipenem+Relebactam
RxNorm normalized name: cilastatin / imipenem / relebactam
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibiotic treatment for KPC producing CRE-containing gram-negative infections
Trial: NCT04790045
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
Trial: NCT04817540
Drug: Herzuma
RxNorm normalized name: Herzuma
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
Trial: NCT06657066
Drug: Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
Trial: NCT06657066
Drug: Control (Standard treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
Trial: NCT06604325
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
Trial: NCT05294900
Drug: paclitaxel/carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5
Trial: NCT04721015
Drug: ABBV-637
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT04721015
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT04721015
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablets
Trial: NCT06672666
Drug: Hemp Derived Cannabidiol Extract
RxNorm normalized name: hemp
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
Trial: NCT04886700
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
Trial: NCT05192213
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
Trial: NCT04831450
Drug: Cemiplimab-Rwlc
RxNorm normalized name: cemiplimab-rwlc
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
Trial: NCT06672549
Drug: Orforglipron
RxNorm normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally. ISA specific interventions will be listed in the ISA.
Trial: NCT05588128
Drug: 18F-DCFpyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to Cohort.
Trial: NCT06387056
Drug: Rezvilutamide
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg by mouth once a day for 24 weeks.
Trial: NCT06387056
Drug: Goserelin Microspheres for Injection
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.
Trial: NCT06387056
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Trial: NCT06387056
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg by mouth twice a day for 20 weeks.
Trial: NCT06387056
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Trial: NCT06387056
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Trial: NCT06187506
Drug: Disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg, administered intravenously every three weeks
Trial: NCT00189358
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04349930
Drug: Cannabidiol vaginal suppository
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol vaginal suppository
Trial: NCT05476796
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
Trial: NCT05476796
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Trial: NCT01218022
Drug: Losartan Potassium Tablets
RxNorm normalized name: Losartan Potassium Tablets
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06342362
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
Trial: NCT05564858
Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FDA022-BB05, intravenously infusion, q3w
Trial: NCT04902885
Drug: Trilaciclib, carboplatin, etoposide，or Topotecan
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
Trial: NCT04902885
Drug: placebo, carboplatin, etoposide，or Topotecan
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
Trial: NCT05213169
Drug: Apomorphine Hydrochloride 5mg/ml
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Product administered using an external continuous subcutaneous infusion pump.
Trial: NCT05841849
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
Trial: NCT05841849
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
Trial: NCT05841849
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous fosaprepitant 150mg for D1 before chemotherapy
Trial: NCT02723435
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05749588
Drug: A2: SHR-A1811 with Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody
Trial: NCT06411184
Drug: Regulator T Cells
RxNorm normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
Trial: NCT04207710
Drug: Gebauer's Ethyl Chloride
RxNorm normalized name: Gebauer's Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical refrigerant spray
Trial: NCT04718064
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
Trial: NCT04670653
Drug: MOMETASONE FUROATE
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray
Trial: NCT05008887
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
Trial: NCT05962307
Drug: Bulevirtide
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: dose of 2 mg/day subcutaneously
Trial: NCT04788563
Drug: Original antihypertensive treatment (compulsively randomized arm)
RxNorm normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Trial: NCT04788563
Drug: Original antihypertensive treatment (voluntarily randomized arm)
RxNorm normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Trial: NCT04987203
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tivozanib will be administered orally.
Trial: NCT04987203
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered via intravenous infusion.
Trial: NCT04926155
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Trial: NCT06184698
Drug: liposomal irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: liposomal irinotecan 70 mg/m²
Trial: NCT06184698
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2400 mg/m²
Trial: NCT06184698
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 5 mg/kg
Trial: NCT01218724
Drug: Losartan Potassium and Hydrochlorothiazide Tablets
RxNorm normalized name: Losartan Potassium and Hydrochlorothiazide Tablets
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04924257
Drug: Esketamine nasal spray
RxNorm normalized name: esketamine Nasal Spray
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
Trial: NCT00006072
Drug: Rituxan
RxNorm normalized name: Rituxan
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04015557
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Trial: NCT04676243
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg coated tablets, orally administered
Trial: NCT05804162
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
Trial: NCT05804162
Drug: Cagrilintide Placebo
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive cagrilintide placebo subcutaneously once weekly.
Trial: NCT05804162
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Partcipants will receive a single dose of moxifloxacin orally.
Trial: NCT05804162
Drug: Moxifloxacin Placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Partcipants will receive a single dose of moxifloxacin orally.
Trial: NCT05352191
Drug: Beclomethasone
RxNorm normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled 800ug
Trial: NCT04734379
Drug: Fasudil
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral fasudil 180 mg/day
Trial: NCT05065021
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
Trial: NCT05065021
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
Trial: NCT05065021
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
Trial: NCT05065021
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
Trial: NCT05463133
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
Trial: NCT05463133
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
Trial: NCT05463133
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
Trial: NCT05463133
Drug: Emapalumab-Izsg
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
Trial: NCT05463133
Drug: Tociluzumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
Trial: NCT05160857
Drug: Herombopag Olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
Trial: NCT05597735
Drug: Tecovirimat
RxNorm normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.
Trial: NCT06127212
Drug: Dapagliflozin 10 mg film-coated tablet
RxNorm normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
Trial: NCT05842798
Drug: TNM002
DrugBank: M002 (DB18318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNM002, intramuscular injection
Trial: NCT05187169
Drug: VS-6766
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAF/MEK inhibitor
Trial: NCT05936086
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
Trial: NCT05936086
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.